Superoxide production by neutrophils in children with malignant tumors treated with recombinant human granulocyte colony-stimulating factor

Haematologica. 1995 Jan-Feb;80(1):13-7.

Abstract

Background: Human recombinant granulocyte colony-stimulating factor (rhG-CSF), widely used to combat chemotherapy-induced neutropenia, stimulates both in vivo and in vitro intra- and extra-cellular O2- production in human polymorphonuclear cells (PMNs).

Patients and methods: Twelve patients with solid tumors or acute lymphoblastic leukemia were treated during induced aplasia with rhG-CSF (5 micrograms/kg/day). Intra- and extracellular O2- production by PMNs isolated from these patients after 5 days of rhG-CSF therapy was assessed following both fMLP and PMA stimulation.

Results: All patients showed a rise in PMN count; administration of rhG-CSF enhanced intra- and extracellular O2- release after fMLP but not after PMA stimulation.

Conclusions: rhG-CSF potentiates in vivo O2- production by PMNs stimulated with receptor-mediated agonists via G-protein (e.g. fMLP), but not by those stimulated with agonists that bypass receptors via protein kinase C (e.g. PMA).

MeSH terms

  • Adolescent
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Infant
  • Male
  • Neoplasms / blood
  • Neoplasms / drug therapy*
  • Neutrophils / metabolism*
  • Recombinant Proteins / therapeutic use
  • Superoxides / blood*

Substances

  • Recombinant Proteins
  • Superoxides
  • Granulocyte Colony-Stimulating Factor